BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 3044442)

  • 1. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67.
    Lokhorst HM; Boom SE; Terpstra W; Roholl P; Gerdes J; Bast BJ
    Br J Haematol; 1988 Aug; 69(4):477-81. PubMed ID: 3044442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
    Boccadoro M; Durie BG; Frutiger Y; Gavarotti P; Redoglia V; Massaia M; D'Alberto M; Marmont F; Gallamini A; Tribalto M
    Acta Haematol; 1987; 78(4):239-42. PubMed ID: 3122489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of plasma cell infiltrates in the bone marrow. A clinicopathological study on 80 patients including immunohistochemistry and morphometry.
    Thiele J; Arenz B; Klein H; Vierbuchen M; Zankovich R; Fischer R
    Virchows Arch A Pathol Anat Histopathol; 1988; 412(6):553-62. PubMed ID: 3129867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic value of the MB2 monoclonal antibody in paraffin-embedded bone marrow sections of patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
    Dehou MF; Schots R; Lacor P; Arras N; Verhavert P; Klöppel G; van Camp B
    Am J Clin Pathol; 1990 Sep; 94(3):287-91. PubMed ID: 1697732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy.
    Boccadoro M; Gavarotti P; Fossati G; Pileri A; Marmont F; Neretto G; Gallamini A; Volta C; Tribalto M; Testa MG
    Br J Haematol; 1984 Dec; 58(4):689-96. PubMed ID: 6518137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
    Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
    Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell morphology in multiple myeloma and related disorders.
    Ribourtout B; Zandecki M
    Morphologie; 2015 Jun; 99(325):38-62. PubMed ID: 25899140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of the immunoperoxidase technic to bone marrow trephine biopsies in the classification of patients with monoclonal gammopathies.
    Peterson LC; Brown BA; Crosson JT; Mladenovic J
    Am J Clin Pathol; 1986 Jun; 85(6):688-93. PubMed ID: 3085474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
    Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
    Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.
    Requirand G; Robert N; Boireau S; Vincent L; Seckinger A; Bouhya S; Ceballos P; Cartron G; Hose D; Klein B; Moreaux J
    Cytometry B Clin Cytom; 2019 May; 96(3):209-214. PubMed ID: 30417559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interpretation of minimal medullary plasmacytoses in monoclonal dysglobulinemias. Importance of the study of osteomedullary biopsies of semi-thin sections and immunologic marking].
    Canioni D; Kermarec J
    Ann Pathol; 1982; 2(4):279-92. PubMed ID: 6760876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal gammopathy of undetermined significance: a new proposal of workup.
    Mangiacavalli S; Cocito F; Pochintesta L; Pascutto C; Ferretti V; Varettoni M; Zappasodi P; Pompa A; Landini B; Cazzola M; Corso A
    Eur J Haematol; 2013 Oct; 91(4):356-60. PubMed ID: 23859528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel type of proliferating lymphoplasmacytoid cell with a characteristic spotted immunofluorescence pattern.
    Lokhorst HM; Boom SE; Bast BJ; Peters PJ; Tedder TF; Gerdes J; Petersen E; Ballieux RE
    J Clin Invest; 1987 May; 79(5):1401-11. PubMed ID: 3553239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.
    Greipp PR; Kyle RA
    Blood; 1983 Jul; 62(1):166-71. PubMed ID: 6407546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies.
    Falini B; Canino S; Sacchi S; Ciani C; Martelli MF; Gerdes J; Stein H; Pileri S; Gobbi M; Fagioli M
    Br J Haematol; 1988 Jul; 69(3):311-20. PubMed ID: 3165668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CD52 on plasma cells in plasma cell proliferative disorders.
    Kumar S; Kimlinger TK; Lust JA; Donovan K; Witzig TE
    Blood; 2003 Aug; 102(3):1075-7. PubMed ID: 12714489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
    Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
    Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.